Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Changjie Lou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0002-9925-3667; OpenAlex author ID A5036829953. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 3 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 11

  1. TRIM21 Promotes Tumor Growth and Gemcitabine Resistance in Pancreatic Cancer by Inhibiting EPHX1-Mediated Arachidonic Acid Metabolism. Co-author DOI 10.1002/advs.202413674↗
  2. Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyae207↗
  3. Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer. Co-author DOI 10.1186/s12885-023-10653-4↗
  4. HOXB9 blocks cell cycle progression to inhibit pancreatic cancer cell proliferation through the DNMT1/RBL2/c-Myc axis. Co-author DOI 10.1016/j.canlet.2022.215595↗
  5. Systemic Inflammatory Biomarkers, Especially Fibrinogen to Albumin Ratio, Predict Prognosis in Patients with Pancreatic Cancer. Co-author DOI 10.4143/crt.2020.330↗
  6. LINC01559 accelerates pancreatic cancer cell proliferation and migration through YAP-mediated pathway. Co-author DOI 10.1002/jcp.29288↗
  7. A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer. Co-author DOI 10.12659/msm.927654↗
  8. Ginkgolide B enhances gemcitabine sensitivity in pancreatic cancer cell lines via inhibiting PAFR/NF-кB pathway. Co-author DOI 10.1016/j.biopha.2018.10.084↗
  9. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer. Co-author DOI 10.1042/cs20180816↗
  10. CSN6 expression is associated with pancreatic cancer progression and predicts poor prognosis. Co-author DOI 10.1080/15384047.2019.1632143↗
  11. Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0050956↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yanqiao Zhang · 7 shared papers, 2019–2024 · strength 0.79
  2. Hengzhen Li · 3 shared papers, 2022–2025 · strength 0.50
  3. Xiaona Fan · 2 shared papers, 2024–2025 · strength 0.37
  4. Zhiwei Li · 3 shared papers, 2019–2024 · strength 0.35
  5. Lin Fang · 3 shared papers, 2019–2022 · strength 0.31
  6. Yuanlong Gu · 2 shared papers, 2020–2023 · strength 0.29
  7. Dan Wang · 2 shared papers, 2021–2024 · strength 0.27
  8. Yang Yao · 2 shared papers, 2021–2022 · strength 0.24
  9. Zhiwei Li · 1 shared paper, 2025 · strength 0.21
  10. Zhiwei Li · 2 shared papers, 2019–2020 · strength 0.21
  11. Jie Lian · 2 shared papers, 2019–2021 · strength 0.19
  12. Peiyuan Cai · 1 shared paper, 2023 · strength 0.18
  13. Juan Zhao · 1 shared paper, 2023 · strength 0.18
  14. Tongsen Zheng · 1 shared paper, 2024 · strength 0.16
  15. Yanqiao Zhang · 2 shared papers, 2012–2019 · strength 0.15
  16. Hanzhi Cui · 1 shared paper, 2020 · strength 0.11
  17. Wen Zhang · 1 shared paper, 2020 · strength 0.11
  18. Jun Zhou · 1 shared paper, 2020 · strength 0.11
  19. Aiping Zhou · 1 shared paper, 2020 · strength 0.11
  20. Guochao Deng · 1 shared paper, 2020 · strength 0.11
  21. Guanghai Dai · 1 shared paper, 2020 · strength 0.11
  22. Jiaqi Shi · 1 shared paper, 2019 · strength 0.10
  23. Chao Liu · 1 shared paper, 2019 · strength 0.08
  24. Qi Zhao · 1 shared paper, 2019 · strength 0.08
  25. Jiaqi Shi · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.